FDA OKs Cequent IND for Oral RNAi Drug

The drug is designed to treat advanced familial adenomatous polyposis by inhibiting the oncogene beta-catenin, which is expected to prevent the formation of polyps characterizing the disease and possibly slow the progression to malignancy of existing ones.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.